Hebbring Scott J, Fredriksson Henna, White Kirsten A, Maier Christiane, Ewing Charles, McDonnell Shannon K, Jacobsen Steven J, Cerhan James, Schaid Daniel J, Ikonen Tarja, Autio Ville, Tammela Teuvo L J, Herkommer Kathleen, Paiss Thomas, Vogel Walther, Gielzak Marta, Sauvageot Jurga, Schleutker Johanna, Cooney Kathleen A, Isaacs William, Thibodeau Stephen N
Mayo Clinic Rochester, 200 First Street Southwest, 920 Hilton Building, Rochester, MN 55905, USA.
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):935-8. doi: 10.1158/1055-9965.EPI-05-0910.
The Nijmegen breakage syndrome 1 (NBS1) gene, which participates in DNA double strand break repair, has been postulated to be a susceptibility factor for a number of cancers, including prostate cancer. Numerous mutations have been identified in NBS1, including the founder mutation 657del5. In this study, a number of analyses were done to determine whether mutations in NBS1 are associated with an increased risk for prostate cancer. The frequency of the 657del5 mutation in both familial prostate cancer cases (1,819 affected men among 909 families) and sporadic prostate cancer cases (1,218 affected men) collected from five centers participating in the International Consortium for Prostate Cancer Genetics were compared with that found in 697 normal controls. Seven individuals were identified to carry the mutation among the 3,037 cases screened: four in the familial group (three from one family and one from another) and three in the sporadic cases. The carrier frequency was 0.22% (2 of 909) for the probands and 0.25% (3 of 1,218) for the sporadic cases of prostate cancer. The 657del5 mutation was not detected in either the 293 unaffected members of the prostate cancer families or in the 697 control samples tested. The entire NBS1 gene was also sequenced in 20 of the youngest affected individuals from the Finnish group of familial cases to identify the presence of possible mutations in this high-risk group. One rare (D95N) and one common (E185Q) missense alteration was identified. More detailed analyses of the E185Q polymorphism, along with a third rare variant (R215W), failed to show an association with prostate cancer. Because the 657del5 mutation was absent from the control population, we are unable to determine if this alteration predisposes to prostate cancer. However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples.
参与DNA双链断裂修复的尼美根断裂综合征1(NBS1)基因被认为是包括前列腺癌在内的多种癌症的易感因素。已在NBS1中鉴定出许多突变,包括始祖突变657del5。在本研究中,进行了多项分析以确定NBS1中的突变是否与前列腺癌风险增加相关。将参与国际前列腺癌遗传学会的五个中心收集的家族性前列腺癌病例(909个家族中的1819名患病男性)和散发性前列腺癌病例(1218名患病男性)中657del5突变的频率与697名正常对照中的频率进行比较。在筛查的3037例病例中,有7人被鉴定携带该突变:家族性组中有4人(一个家族中有3人,另一个家族中有1人),散发性病例中有3人。前列腺癌先证者的携带频率为0.22%(909人中的2人),散发性病例的携带频率为0.25%(1218人中的3人)。在前列腺癌家族的293名未患病成员或测试的697份对照样本中均未检测到657del5突变。还对芬兰家族性病例组中20名最年轻的患病个体的整个NBS1基因进行了测序,以确定该高危组中是否存在可能的突变。鉴定出一种罕见的(D95N)和一种常见的(E185Q)错义改变。对E185Q多态性以及第三个罕见变体(R215W)进行更详细的分析,未发现与前列腺癌有关联。由于对照人群中不存在657del5突变,我们无法确定这种改变是否易患前列腺癌。然而,我们的数据确实表明,NBS1内的突变,特别是657del5,对我们患者样本中的总体前列腺癌负担没有显著影响。